226 related articles for article (PubMed ID: 36525555)
21. Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal.
Rose DT; Gandhi SM; Bedard RA; Mondy KE; Chu AL; Gamble KC; Gee AT; Kundra MA; Williams AL; Lee BK
Open Forum Infect Dis; 2022 Jul; 9(7):ofac238. PubMed ID: 35854994
[TBL] [Abstract][Full Text] [Related]
22. Case Report: Nirmatrelvir/Ritonavir and Tacrolimus in a Kidney Transplant Recipient With COVID-19.
Lindauer KE; Hamel AG
Am Fam Physician; 2022 Jun; 105(6):569-570. PubMed ID: 35704835
[No Abstract] [Full Text] [Related]
23. Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal.
Xiong Y; Wang X; Li S; Zhang Q; Guo L; Chen W; Zhao Z; Liu L
Front Pharmacol; 2023; 14():1285078. PubMed ID: 38026995
[TBL] [Abstract][Full Text] [Related]
24. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
Prikis M; Cameron A
Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
[TBL] [Abstract][Full Text] [Related]
25. A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case.
Guyon J; Novion M; Fulda V; Ducint D; Molimard M; Couzi L; Kaminski H; Salvo F; Bouchet S
J Am Soc Mass Spectrom; 2022 Oct; 33(10):1975-1981. PubMed ID: 36084269
[TBL] [Abstract][Full Text] [Related]
26. Tacrolimus toxicity due to enzyme inhibition from ritonavir.
Snee I; Drobina J; Mazer-Amirshahi M
Am J Emerg Med; 2023 Jul; 69():218.e5-218.e7. PubMed ID: 37173153
[TBL] [Abstract][Full Text] [Related]
27. Single-center experience with nirmatrelvir/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression.
Mecadon K; Arvanitis P; Farmakiotis D; Rogers R
Clin Transplant; 2022 Aug; 36(8):e14752. PubMed ID: 35713302
[No Abstract] [Full Text] [Related]
28. Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients.
Xu X; Zhang H; Liu L; Fu Q; Wu C; Lin X; Tang K; Wang C; Chen P
Eur J Clin Pharmacol; 2024 May; ():. PubMed ID: 38691139
[TBL] [Abstract][Full Text] [Related]
29. Elevated Tacrolimus Blood Concentration Due to the Interaction with Nirmatrelvir/Ritonavir During COVID-19 Treatment: A Case Report.
Cordero CG; de Vicente MS
Transplant Proc; 2023 Oct; 55(8):1826-1828. PubMed ID: 37037726
[TBL] [Abstract][Full Text] [Related]
30. Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19.
Zhang W; Zhang X; Han J; Zhang W; Xu J; Zhang X; Bian H; Meng C; Shang D; Zhou Y; Wang D; Feng B
Front Pharmacol; 2024; 15():1389187. PubMed ID: 38601471
[TBL] [Abstract][Full Text] [Related]
31. Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS.
Qin F; Wang H; Li M; Zhuo S; Liu W
Expert Opin Drug Saf; 2023; 22(12):1321-1327. PubMed ID: 37477905
[TBL] [Abstract][Full Text] [Related]
32. Strategies to Mitigate the Drug-Drug Interaction between Nirmatrelvir/Ritonavir and Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Azole Antifungals: Results of a Case Series.
Griffin SP; Lee B; Doh J; Paradyse AR; Jeyakumar D; Arter Z; Nam H; Blodget E; Smith J; Valek A; Vittayawacharin P; Kongtim P; Ciurea SO
Acta Haematol; 2023 Oct; ():1-7. PubMed ID: 38059378
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
Yang H; Yu X; Hou W; Liu X; Chen J; Zhang Y; Wang Y; Zhu Y; Qian Q; Ma K; An Z
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0138423. PubMed ID: 38289075
[TBL] [Abstract][Full Text] [Related]
34. Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID-19.
Singh RSP; LaBadie RR; Toussi SS; Shi H; Berg JK; Neutel JM; Aggarwal S
J Clin Pharmacol; 2024 Feb; 64(2):145-154. PubMed ID: 37751891
[TBL] [Abstract][Full Text] [Related]
35. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study.
van Maarseveen EM; Crommelin HA; Mudrikova T; van den Broek MP; van Zuilen AD
Transplantation; 2013 Jan; 95(2):397-402. PubMed ID: 23250333
[TBL] [Abstract][Full Text] [Related]
36. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD; Depcinski S; Sharma M
Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
[TBL] [Abstract][Full Text] [Related]
37. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
[TBL] [Abstract][Full Text] [Related]
38. Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patient.
Shah A; Nasrullah A; Butt MA; Young M
Eur J Case Rep Intern Med; 2022; 9(9):003528. PubMed ID: 36299835
[TBL] [Abstract][Full Text] [Related]
39. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Bartiromo M; Borchi B; Botta A; Bagalà A; Lugli G; Tilli M; Cavallo A; Xhaferi B; Cutruzzulà R; Vaglio A; Bresci S; Larti A; Bartoloni A; Cirami C
Transpl Infect Dis; 2020 Aug; 22(4):e13286. PubMed ID: 32279418
[TBL] [Abstract][Full Text] [Related]
40. A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.
Leung V; Gill S; Llanes A; Khawaja A; Stagg A; McCready J; Jacubovich M; Ho G; Powis J; Kandel C
PLoS One; 2023; 18(10):e0293302. PubMed ID: 37856531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
